Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909130 | 0.93 | KMT2A (0.46) | GRM2KDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2910978 | 0.90 | NAMPT (0.45) | KDM4ESMN1; SMN2ALDH1A1MAPTNAMPT | |
| SCHEMBL2910411 | 0.89 | GRM2 (0.46) | GRM2ALDH1A1NAMPTNPSR1 | |
| SCHEMBL1157752 | 0.88 | GRM2 (0.44) | GRM2KDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2906999 | 0.87 | MEP1B (0.43) | KDM4ESMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL1157339 | 0.86 | MAPT (0.42) | GRM2KDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1157628 | 0.85 | GRM2 (0.41) | GRM2KDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1157272 | 0.84 | MAPT (0.45) | GRM2KDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1157641 | 0.84 | PDE4A (0.53) | GRM2MAPTHTTGAA | |
| SCHEMBL1157260 | 0.84 | PDE4B (0.41) | GRM2KDM4ESMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1692109-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | Memory Pharmaceuticals Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
| WO-2005061458-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | GRM2 3987/4885KDM4E 252/4885SMN1; SMN2 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.